Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases.Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, [...]

Horizon 2020, the EU framework program for research and development, will grant 2.2 million euros to Lipum’s ongoing development of a biological pharmaceutical for treatment of chronic inflammatory diseases.Lipum has identified the novel target molecule Bile Salt-Stimulated Lipase (BSSL). Preclinical studies have very successfully verified the concept in several well-established models for autoimmune chronic inflammatory [...]